My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Cubana de Medicina
On-line version ISSN 1561-302X
Abstract
SANTANA PEREZ, Felipe and ANDINO VALDES, Nieves. Tratamiento de hiperprolactinemia idiopática con lisurida. Rev cubana med [online]. 1996, vol.35, n.1, pp. 17-23. ISSN 1561-302X.
Lysuride, 8-amino-argolene has a very important agonist activity for dopamine, and hence for prolactin secretion. A clinical trial was carried out in 20 women presenting with non-tumor hyperprolactinemia with the aim of assessing the efficacy and safety of this drug as a therapeutic agent for the treatment of idiopathic hyperprolactinemia in comparison to bromocriptine. Patients were randomly assigned to 2 groups of treatment; Group I received bromocriptine (Parlodel ) in a dose of 2.5 mg/day and Group II received lysuride (Lysemil forte) in a dose of 0.2 mg/day. Plasma prolactin levels (PRL) were determined as follows: Basal PRL and on days 1, 7, 14, 21, and 28 after treatment. No significant statistical differences were found between both drugs regarding plasma prolactin levels. Eight patients from group I and 11 from group II presented with side-effects. Constipation was reported as the most frequent side-effect. It is concluded that lysuride is as effective as bromocriptine for reducing prolactin levels in patients with idiopathic hyperprolactinemia, and that its side-effects are similar to the ones of bromocriptine, but lysuride appears to be cheaper from the economic point of view. That's why we recommend to evaluate its short-term efficacy in order to use it as an alternative effective, safe, and economic treatment modality.
Keywords : HYPERPROLACTINEMIA [drug therapy]; LYSURIDE [therapeutic use]; BROMOCRIPTINE [therapeutic use]; PROLACTIN [blood]; AMENORRHEA, GALACTORRHEA; OLIGOMENORRHEA.